Loading patent…
AssigneeIntercell AG
InventorsUrban Lundberg, Andreas Meinke, Eszter Nagy, Alexander von Gabain, Birgit Noiges, Dieter Gelbmann, Albina Poljak, Christine Triska
Estimating the term…
The present invention relates to isolated nucleic acid molecules which encode a protein, isolated nucleic acid molecules which encode a hyperimmune serum reactive antigen, a vector which comprises such nucleic acid molecule, a host cell comprising such vector, a hyperimmune reactive antigen from Borrelia species, proteins which are preferably hyperimmune serum reactive antigens, hyperimmune serum reactive antigens, antigens, a process for producing such proteins, hyperimmune serum reactive antigens or antigens, a process for producing a cell which expresses such protein, hyperimmune serum reactive antigen or antigen, an antibody binding to such protein, hyperimmune serum reactive antigen or antigen, a hybridoma cell producing such antibody, methods for producing such antibody, a pharmaceutical composition comprising such nucleic acid molecule, protein, hyperimmune serum reactive antigen, antigen or antibody, the use of such nucleic acid molecule, protein, hyperimmune serum reactive antigen, antigen or antibody for the manufacture of a medicament, methods for identifying an antagonist capable of reducing or inhibiting the interaction activity of such protein, hyperimmune serum reactive antigen or antigen, methods for diagnosing an infection and methods for the treatment of an infection. More specifically such proteins, hyperimmune serum reactive antigens or antigens are produced by or associated with bacterial pathogens causing Lyme disease or bacterial infections caused by Borrelia burgdorferi s.l.
An isolated nucleic acid molecule encoding a protein, comprising a nucleic acid sequence, which is selected from the group consisting of:
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
A protein, having an amino acid sequence selected from the group consisting of Seq ID Nos 135 to 268, 388 to 506, and 629 to 750, or an active fragment or an active variant thereof, wherein the protein is a hyperimmune serum reactive antigen, or a fragment thereof, if the amino acid sequence is selected from the group consisting of Seq ID Nos. 388 to 506 and 629 to 750.
(canceled)
(canceled)
(canceled)
An antigen, whereby the antigen comprises a core amino acid sequence as indicated in column “Predicted immunogenic aa” and “Location of identified immunogenic region” of Table 1, as indicated in column “aa (start-stop)” of Table 5, as defined by columns “From aa” and “To aa” of Table 6, or as defined by column “Amino acid From-To” of Table 8 or, such antigen comprises a core amino acid sequence selected from the group consisting of:
-26. (canceled)
(canceled)
(canceled)
(canceled)
-41. (canceled)
-48. (canceled)
A method for the treatment of a Borrelia infection in an animal or man in need thereof, comprising the step of administering to said animal or man a therapeutically effective amount of a pharmaceutical composition 14 or 15.
(canceled)
(canceled)
Dependencies are inferred from the claim text.